This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.
therapies. Boehringer is a diabetes specialist and already has a dual GLP-1 and glucagon agonist, partnered with Zealand Pharma, in phase 1b testing. ... later this year, as well as a drug candidates for the disease covered by its recently expanded $201m
The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to
The French pharma group paid $245m for the voucher - which cuts four months of the FDA's usual review time - in a deal with Retrophin earlier this year. ... Lixisenatide is a once-daily GLP-1 agonist that was invented by Zealand Pharma and has been sold
Zealand Pharma said potential choices include medicines that require once-weekly dosing, something that could give it an edge over the current leading GLP-1 agonist, Novo Nordisk's Victoza (liraglutide), ... Zealand has existing interests in the field of
Lyxumia's approval is good news too for the drug's inventors Zealand Pharma who signed a deal with Sanofi to further develop the drug. ... Zealand also said it is eligible to receive remaining development, regulatory and sales milestone payments of up to
As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.
For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma
Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.
He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has
Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm. . ... The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and
She leaves after five years with the Danish biotech company. Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities. . ... served as a member of AstraZeneca's strategic planning business development organisation
More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...